However, Cox regression analysis demonstrated that higher CYBB expression was an independent risk factor for significantly poorer progression-free survival in patients with GBM after the adjustment for subtypes (hazard risk = 1.6; 95% confidence interval = 1.05–2.4; p = 0.029) (Figure 2E). The gene discussed is CYBB; the disease is glioblastoma.